For the establishment of the basis of treatment and study in the patients of facial bone fracture, we performed a clinico-statistical study about 28 papers and 9564 cases reported as facial bone fractures in the journal of Korean association of oral and maxillofacial surgeons, the journal of the Korean academy of maxillofacial plastic and reconstructive surgery, and related journals. The results were as follows: 1. The ratio of men to women was 4.50:1. 2. The age frequency was highest in the third decade(37.6%), and fourth(21.5%), second(15.5%), fifth(10.3%) decade in orders. 3. The most common location of facial bone fractures was the mandible(62.7%), and zygoma complex (22.6%), nasal bone(15.0%), and maxilla(13.0%) were next in order of frequency. 4. The major etiologic factors were traffic accident(37.9% ), fisticuffs(26.4%), and falldown and slip down(23.4%). 5. The frequent fracture site of mandible is symphysis(39.3%), angle(24,4% ), and condyle(22.5%). The ratio of left to right was 1.31:1. Open reduction(69.1%) was the more frequently using method of treatment in mandibular fracture than colsed reduction (28.6%). 6. The sites of zygoinatic fractures were zygoma complex(48.0%), zygornatic arch(35.7%), and combined(16.3%). The left to right ratio was 1.37:1. 7. The most frequent maxillary fracture was Le Fort I (31.4% ), and Le Fort II (27.1%), unilateral(14.3%), Le Fort III (7.6%) were next in order of frequency.
Facial Bones* ; Female ; Humans ; Male ; Mandible ; Mandibular Fractures ; Maxillary Fractures ; Plastics ; Statistics as Topic* ; Zygoma

BACKGROUND: Previous reports have suggested that alleles at the plasminogen activator inhibitor-1 (PAI-1) gene are associated with increased risk of developing coronary artery disease, including myocardial infarction and stroke through their effect on PAI-1 levels. Method: We attempted to search English literatures for all reports of possible effects of PAI-1 gene on cardiovascular disease in human published prior to November 1998. We used a Mantel-Haenszel method (fixed effect model) and random effect model, respectively, to perform a meta-analysis of 7 case-control studies that provided information related to the effects of PAI-1 gene on risk of cardiovascular disease. RESULTS: From 7 studies for diagnosed cardiovascular disease, the relative frequencies of the three genotypes among controls was (5G/5G) (homozygous normal), 24.5%; (4G/5G) (heterozygous), 48.2%, and (4G/4G) (homozygous for the mutant, 675 GGGG), 27.3%. These relative frequencies in cases were 21.7% for 5G/5G, 48.0% for 4G/5G, and 30.3% for 4G/4G. In fixed effect model, compared with those with genotype (5G/5G), the overall odds ratio (OR) for cardiovascular disease among those with (4G/5G) was 1.12 (95% CI, 0.93 to 1.34), and it was 1.20 (1.01 to 1.44) for the (4G/4G) genotype. For five studies with myocardial infarction as the outcome, the overall OR of myocardial infarction was 1.20 (0.99 to 1.47) for those with (4G/5G) and 1.24 (1.00, 1.54) for those with (4G/4G) genotypes, respectively. CONCLUSION: Our findings provide support for the weak association between PAI-1 gene and cardiovascular disease, in particular, myocardial infarction.
Alleles ; Cardiovascular Diseases* ; Case-Control Studies* ; Coronary Artery Disease ; Genotype ; Humans ; Myocardial Infarction ; Odds Ratio ; Plasminogen Activator Inhibitor 1* ; Plasminogen Activators ; Polymorphism, Genetic* ; Stroke

Chorionic villus sampling has gained importance as a tool for early cytogenetic diagnosis with a shift toward first trimester screening. First trimester screening using nuchal translucency and biomarkers is effective for screening. Chorionic villus sampling generally is performed at 10-12 weeks by either the transcervical or transabdominal approach. There are two methods of analysis; the direct method and the culture method. While the direct method may prevent maternal cell contamination, the culture method may be more representative of the true fetal karyotype. There is a concern for mosaicism which occurs in approximately 1% of cases, and mosaic results require genetic counseling and follow-up amniocentesis or fetal blood sampling. In terms of complications, procedure-related pregnancy loss rates may be the same as those for amniocentesis when undertaken in experienced centers. When the procedure is performed after 9 weeks gestation, the risk of limb reduction is not greater than the risk in the general population. At present, chorionic villus sampling is the gold standard method for early fetal karyotyping; however, we anticipate that improvements in noninvasive prenatal testing methods, such as cell free fetal DNA testing, will reduce the need for invasive procedures in the near future.
Amniocentesis ; Biomarkers ; Chorionic Villi Sampling* ; Cytogenetics ; Diagnosis ; DNA ; Extremities ; Female ; Fetal Blood ; Genetic Counseling ; Humans ; Karyotype ; Karyotyping ; Mass Screening ; Mosaicism ; Nuchal Translucency Measurement ; Pregnancy ; Pregnancy Trimester, First

No abstract available.
Ear*

Antibodies, Antinuclear ; Arthritis, Rheumatoid ; Autoimmune Diseases ; Biopsy ; Brain ; Butterflies ; Drug Therapy ; Endothelium ; Female ; Humans ; Immune System ; Liver ; Lupus Erythematosus, Systemic ; Lymph Nodes ; Lymphoma ; Maxilla ; Middle Aged ; Oncogenic Viruses ; Sjogren's Syndrome

Genioplasty ; Humans ; Incisor ; Lip ; Maxillary Osteotomy ; Orthognathic Surgery ; Osteotomy ; Osteotomy, Sagittal Split Ramus ; Prognathism ; Surgery, Oral

The retraction of anterior teeth could be performed more easier by inducing of skeletal anchorage system rather than by conventional method on orthodontic treatment. But, we wonder how effective the system draws well without anchorage loss and draws anterior teeth aside posteriorly, and if the system can reduce the time, in comparison with the anchorage of posterior teeth. For that reason we have studied on the subject of patients, who were required the maximum anchorage on orthodontic treatment and the cases without crowding. The subjects of the experimental group are 35 areas of 20 people who were inserted miniscrews after Mx or Mn 1st premolar extracted. Also, the subjects of the control group are 81 areas of 45 people who were not inserted miniscrews. Compared the anchorage loss of experimental group with control one, we could get the result that the anchorage loss of experimental group is 1.034+/-0.891mm and control group is 2.790+/-1.882mm(P<0.01). Compared the space closing time of experimental group with control one, we could get the result that the space closing time of experimental group is 369.40+/-110.81days and control group is 406.56+/-231.63days. But the result of comparing space closing time has no significance in statistics. We recognized that the experimental group is more faster than the control group in the canine retraction velocity from the result ; the speed of a experimental group has as much as 0.60+/-0.23mm/30days while the speed of a control group has 0.44+/-0.35mm/30days(P<0.05). So, we could convince that orthodontic miniscrew is used effectively in the cases required the maximum anchorage.
Bicuspid ; Crowding ; Humans ; Tooth*

No abstract available.
Child ; Humans ; Humerus

The development and progression of oral cancer is associated with an accumulation of multiple genetic alterations through the multistep processes. Comparative genomic hybridization(CGH), newly developed cytogenetic and molecular biologic technique, has been widely accepted as a useful method to allow the detection of genetic imbalance in solid tumors and the screening for chromosome sites frequently affected by gains or losses in DNA copy number. The authors examined 19 primary oral squamous cell carcinomas using CGH to identify altered chromosome regions that might contain novel oncogenes and tumor suppressor genes. Interrelationship between these genetic aberrations detected and major oncogenes and tumor suppressor genes previously recognized in carcinogenesis of oral cancers was studied. 1. Changes in DNA copy number were detected in 14 of 19 oral cancers (78.9%, mean: 5.58, range: 3~13). High level amplification was present in 4 cases at 9p23, 12p21.1~q13.1, 3q and 8q24~24.3. Fourteen cases(78.9%, mean: 3.00, range: 1~8) showed gains of DNA copy number and 12 cases(70.5%, mean: 2.58, range: 1~9) revealed losses of DNA copy number. 2. The most common gains were detected on 3q(52.6%), 5p(21.0%), 8q(21.0%), 9p(21.0%), and 11q(21.0%). The losses of DNA copy number were frequently occurred at 9p(36.8%), 17q(36.8%), 13q(26.3%), 4p(21.0%) and 9p(21.0%). 3. The minimal common regions of gains were repeatedly observed at 3q24~26.7, 3q27~29, 1q22~31, 5p12~13.3, 8q23~24, and 11q13.1-13.3. The minimal common regions of losses were detected at 9q11~21.3, 17p31, 13q22~34, and 14p16. 4. In comparison of CGH results with tumor stages, the lower stage group showed more frequent gain at 3q, 5q, 9p, and 14q, whereas gains at 1q(1q22~31) and 11q(11q13.1~13.3) were mainly detected in higher stage group. The loss at 13q22~34 was exclusively detected in higher stage. The results indicate that the most frequent genetic alterations in the development of oral cancers were gains at 3q24~26.3, 1q22~31, and 5p12~13.3 and losses at 9q11~21.3, 17p31, and 13q. It is suggested that genetic alterations manifested as gains at 3q24~26.3, 3q27~29, 5p12~13.3 and 5p are associated with the early progression of oral cancer. Gains at 1q22~31 and 11q13.1~13.3 and loss at 13q22-34 could be involved in the late progression of oral cancers.
Carcinogenesis ; Carcinoma, Squamous Cell ; Comparative Genomic Hybridization* ; Cytogenetics ; DNA ; Genes, Tumor Suppressor ; Humans* ; Mass Screening ; Mouth Neoplasms* ; Oncogenes

OBJECTIVE: The aim of this study was to compare midtrimester maternal plasma concentrations of angiopoietin 1, angiopoietin 2, and placental growth factor between pregnant women who subsequently developed preeclampsia and those who did not. METHODS: Midtrimester maternal plasma was collected and stored at -70degrees C when genetic amniocentesis was performed. Cases included 37 samples of individual who subsequently developed preeclampsia, and matched controls were from individuals who did not develop preeclampsia. Angiopoietin 1, angiopoietin 2, and placental growth factor concentrations were measured by the enzyme-linked immunosorbent assay method and were compared using the Mann-Whitney U-test. A P-value <0.05 was considered significant. RESULTS: In pregnant women who subsequently developed preeclampsia, midtrimester maternal plasma concentrations of angiopoietin 1 and angiopoietin 2 were significantly higher and placental growth factor concentrations were significantly lower than in women who did not develop preeclampsia (angiopoietin 1: 10.6 [3.1-19.7] vs. 7.8 [0.9-24.4] ng/mL, P=0.031; angiopoietin 2: 31.0 [4.7-81.2] vs. 18.4 [4.2-49.7] ng/mL, P<0.001; placental growth factor: 87.1 [14.2-774.3] vs. 148.8 [57.2-425.6] pg/mL, P<0.001). Within the case group who subsequently developed preeclampsia, the placental growth factor was significantly lower in those who had fetal growth restrictions than in those who did not (placental growth factor: 72.5 [14.2-774.3] vs. 140.9 [44.2-257.5] pg/mL, P=0.003). CONCLUSION: Midtrimester maternal plasma concentrations of angiopoietin 1, angiopoietin 2, and placental growth factor may be associated with the subsequent development of preeclampsia.
Amniocentesis ; Angiopoietin-1* ; Angiopoietin-2* ; Enzyme-Linked Immunosorbent Assay ; Female ; Fetal Development ; Humans ; Plasma* ; Pre-Eclampsia* ; Pregnancy ; Pregnancy Trimester, Second* ; Pregnant Women*